| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_76ba102ea9c02b6633d64bf09c5b89a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8214
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8257
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1664
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48261
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-15001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-17023
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48338 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-48 |
| filingDate |
2016-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7acd4a46f0cb29226a4f480d3d047f7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e293758f5038ec22862b572ec96bb344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c703698022706ded30ae5b549ae8318 |
| publicationDate |
2016-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016331816-A1 |
| titleOfInvention |
Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimentally induced ocular disorders |
| abstract |
Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration. n Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018133139-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018209227-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022246041-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11220528-B2 |
| priorityDate |
2013-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |